No Data
No Data
As of July 10, 2024, Tianjin Tianyao Pharmaceuticals (600488.SH) has 42,882 shareholders.
Tianjin Tianyao Pharmaceuticals (600488.SH) stated on the investor interaction platform on July 11 that as of July 10, 2024, the number of shareholders in the company was 42,882.
Tianjin Tianyao Pharmaceuticals (600488.SH): Tianyao Biotechnology intends to entrust the company to carry out the JYSW003 systematic pre-clinical research project.
On July 10th, Gelonhui reported that Tianjin Tianyao Pharmaceuticals (600488.SH) commissioned Jinyao Biotechnology to conduct preclinical research work on the JYSW003 systemic research project to accelerate the research and development declaration process and enhance the synergy effect of research and development resources. Both parties signed the "Technical Development (Commissioned) Contract" with an amount of 10 million yuan. As of the date of this announcement, in the past 12 months, the transactions between the company and its holding subsidiaries and the same related parties totaled 145.8666 million yuan, which did not exceed 5% of the company's most recent audited net assets, in accordance with the "Stock Listing Rules of the Shanghai Stock Exchange" and the "Company's Articles of Association".
Tianjin Tianyao Pharmaceuticals (600488.SH): Received notification of approval of the application for listing of chemical raw materials for famotidine.
Tianjin Tianyao Pharmaceuticals (600488.SH) announced that it has received the Approval Notice for the Marketing Authorization Application of Famotidine Chemical Raw Materials from the National Medical Products Administration. Famotidine is a guanidine-thiazole H2 receptor blocker with high affinity for H2 receptors. It can effectively inhibit the secretion of basal gastric acid, nocturnal gastric acid, and food-stimulated gastric acid, as well as the secretion of gastric protease as well.
As of June 20th, 2024, Tianjin Tianyao Pharmaceuticals (600488.SH) had a total of 42,947 shareholders.
On June 24th, Gelunhui reported that as of June 20th, 2024, Tianjin Tianyao Pharmaceuticals (600488. SH) had a total of 42,947 shareholders on their investor interaction platform.
Here's Why Tianjin Tianyao Pharmaceuticals (SHSE:600488) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it seems
Tianjin Tianyao Pharmaceuticals (600488.SH) plans to pay a dividend of 0.087 yuan per share in 2023, with a record date of June 14th.
Tianjin Tianyao Pharmaceuticals (600488.SH) announced that it plans to distribute a cash dividend of 0.087 yuan per share for the 2023 fiscal year.
No Data